Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Mendus

    MCap

    SEK512m

    Last close

    SEK10.15

    ▲ 2.15 (26.88%)

    Softcat

    MCap

    GBP3,369m

    Last close

    GBP16.86

    ▲ 154.00 (10.05%)

    EML Payments

    MCap

    AUD251m

    Last close

    AUD0.67

    ▲ 0.06 (9.92%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Newron Pharmaceuticals (SIX: NWRN)

Last close As at 26/10/2024

CHF8.56

▲ −0.26 (−2.95%)

Market capitalisation

CHF165m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is sold in Europe, Japan, the United States and other territories. While generic manufacturers had notified the FDA of their intent to file generic products, Newron and its partners reached settlement agreements and resolved the legal action. Xadago is patent protected until at least December 2027.

Latest Insights

View More

Healthcare | Update

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Healthcare | Flash note

Newron Pharmaceuticals — Evenamide road to registration and beyond

Healthcare | Flash note

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Healthcare | Flash note

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber

    CEO

Balance Sheet

Forecast net cash (€m)

18

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 12.6 5.7 87.7
Relative 11.5 5.9 60.0
52 week high/low CHF11.0/CHF4.2

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, positive results were shared from a Phase II/III trial (study 008A) in schizophrenia patients taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, a partnership deal for evenamide is expected to be secured in the coming months, ahead of a H125 launch for the subsequent, potentially pivotal, multinational Phase III TRS programme. In FY23, Newron recorded total revenue of €9.1m (up 48.6% y-o-y), primarily derived from Xadago-related royalty income.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023A 9.1 (11.2) (16.0) (89.81) N/A N/A
2024E 24.3 6.2 1.5 6.35 143.6 145499.6
2025E 7.3 (4.4) (8.3) (43.06) N/A N/A

Research

Flash note

Healthcare

Newron Pharmaceuticals — Evenamide road to registration and beyond

Flash note

Healthcare

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Healthcare

Update

Newron Pharmaceuticals — Moving full steam towards pivotal studies
View All

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free